FeesSafety
Pluang+

Bladex reports 15% profit rise in Q3 2026, driven by record net interest income and strong fee growth.

Company Fundamentals
27 Oct 2026, 00:30 WIB
PRNewsWire
View Source
Bullish
Bladex reports 15% profit rise in Q3 2026, driven by record net interest income and strong fee growth.

Bladex, a Panama-based multinational bank, announced a 15% year-on-year profit increase to $63.2 million in Q3 2026, supported by record net interest income of $79.8 million and a 26% rise in fees and non-interest income. The bank's credit portfolio grew 35% year-on-year to $16.6 billion, with strong commercial loan growth and solid asset quality. Efficiency remained high with a 25.8% ratio, and capital adequacy ratios stayed well above regulatory minimums. Bladex also declared a quarterly dividend, reflecting confidence in ongoing profitable growth and strategic execution in the Latin American and Caribbean region.

Bladex's Q3 2026 net profit announcement provides context for financial markets. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 27, 2026 04:31 WIB: out of 142 priced US Financials stocks, 81 rose and 61 fell. Notable movers include BMNR at USD 20.96 with a -6.43% change, WULF at USD 12.02 with +6.18%, and AVAT at USD 1.16 with -6.07%.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App